Literature DB >> 22049033

Can we use a lower dose of liposomal amphotericin B for the treatment of mucosal American leishmaniasis?

Valdir S Amato1, Felipe F Tuon, Raphael A Camargo, Regina M Souza, Carolina R Santos, Antonio C Nicodemo.   

Abstract

Liposomal amphotericin B has been used as an alternative treatment of mucosal leishmaniasis, but the optimal dose is not established. We retrospectively reviewed the clinical outcome of eight patients with mucosal leishmaniasis treated with liposomal amphotericin B. The mean total dose was 35 mg/kg (range 24-50 mg/kg), which resulted in the healing of all the lesions in all patients and no recurrences were observed during the follow-up period (mean 25 months; range 7-40 months).

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22049033      PMCID： PMC3205625          DOI： 10.4269/ajtmh.2011.11-0287

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN： 0002-9637            Impact factor:   2.345


  10 in total

1.  Mucocutaneous leishmaniasis associated with HIV infection treated successfully with liposomal amphotericin B (AmBisome)

Authors:  V S Amato; A C Nicodemo; J G Amato; M Boulos; V A Neto
Journal:  J Antimicrob Chemother       Date:  2000-08       Impact factor: 5.790

2.  Liposomal amphotericin B for the treatment of visceral leishmaniasis.

Authors:  Caryn Bern; Jill Adler-Moore; Juan Berenguer; Marleen Boelaert; Margriet den Boer; Robert N Davidson; Concepcion Figueras; Luigi Gradoni; Dimitris A Kafetzis; Koert Ritmeijer; Eric Rosenthal; Catherine Royce; Rosario Russo; Shyam Sundar; Jorge Alvar
Journal:  Clin Infect Dis       Date:  2006-08-28       Impact factor: 9.079

3.  Amphotericin B tissue distribution in autopsy material after treatment with liposomal amphotericin B and amphotericin B colloidal dispersion.

Authors:  Helene Vogelsinger; Stefan Weiler; Angela Djanani; Jordan Kountchev; Rosa Bellmann-Weiler; Christian J Wiedermann; Romuald Bellmann
Journal:  J Antimicrob Chemother       Date:  2006-04-20       Impact factor: 5.790

4.  Mucosal leishmaniasis unresponsive to glucantime therapy successfully treated with AmBisome.

Authors:  R Nonata; R Sampaio; P D Marsden
Journal:  Trans R Soc Trop Med Hyg       Date:  1997 Jan-Feb       Impact factor: 2.184

5.  Mucosal leishmaniasis and abnormalities on computed tomographic scans of paranasal sinuses.

Authors:  Raphael A Camargo; Felipe F Tuon; Daniel V Sumi; Eloisa M Gebrim; Rui Imamura; Antonio C Nicodemo; Giovanni G Cerri; Valdir S Amato
Journal:  Am J Trop Med Hyg       Date:  2010-09       Impact factor: 2.345

6.  Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial.

Authors:  Shyam Sundar; Prabhat Kumar Sinha; Madhukar Rai; Deepak Kumar Verma; Kumar Nawin; Shanawwaj Alam; Jaya Chakravarty; Michel Vaillant; Neena Verma; Krishna Pandey; Poonam Kumari; Chandra Shekhar Lal; Rakesh Arora; Bhawna Sharma; Sally Ellis; Nathalie Strub-Wourgaft; Manica Balasegaram; Piero Olliaro; Pradeep Das; Farrokh Modabber
Journal:  Lancet       Date:  2011-01-20       Impact factor: 79.321

Review 7.  Cutaneous leishmaniasis.

Authors:  Richard Reithinger; Jean-Claude Dujardin; Hechmi Louzir; Claude Pirmez; Bruce Alexander; Simon Brooker
Journal:  Lancet Infect Dis       Date:  2007-09       Impact factor: 25.071

8.  Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations.

Authors:  Shyam Sundar; Himanshu Mehta; A V Suresh; Shri P Singh; Madhukar Rai; Henry W Murray
Journal:  Clin Infect Dis       Date:  2004-01-13       Impact factor: 9.079

9.  Mucosal leishmaniasis: description of case management approaches and analysis of risk factors for treatment failure in a cohort of 140 patients in Brazil.

Authors:  V S Amato; F F Tuon; R Imamura; R Abegão de Camargo; M I Duarte; V A Neto
Journal:  J Eur Acad Dermatol Venereol       Date:  2009-05-04       Impact factor: 6.166

Review 10.  Treatment of mucosal leishmaniasis in Latin America: systematic review.

Authors:  Valdir Sabbaga Amato; Felipe Francisco Tuon; Andre Machado Siqueira; Antonio Carlos Nicodemo; Vicente Amato Neto
Journal:  Am J Trop Med Hyg       Date:  2007-08       Impact factor: 2.345
  10 in total
  15 in total

Review 1.  Leishmaniasis in the United States: treatment in 2012.

Authors:  Henry W Murray
Journal:  Am J Trop Med Hyg       Date:  2012-03       Impact factor: 2.345

Review 2.  Therapeutic options for old world cutaneous leishmaniasis and new world cutaneous and mucocutaneous leishmaniasis.

Authors:  Begoña Monge-Maillo; Rogelio López-Vélez
Journal:  Drugs       Date:  2013-11       Impact factor: 9.546

3.  Lipid nanoparticles for amphotericin delivery in the treatment of American tegumentary leishmaniasis.

Authors:  Regina Maia de Souza; Raul Cavalcante Maranhão; Elaine Rufo Tavares; Fabíola Branco Filippin-Monteiro; Antônio Carlos Nicodemo; Aleksandra Tiemi Morikawa; Edite Hatsumi Yamashiro Kanashiro; Valdir Sabbaga Amato
Journal:  Drug Deliv Transl Res       Date:  2020-04       Impact factor: 4.617

4.  Efficacy and Safety of Liposomal Amphotericin B for the Treatment of Mucosal Leishmaniasis from the New World: A Retrospective Study.

Authors:  Mirella A Cunha; Aline C Q Leão; Rita de Cassia Soler; José Angelo L Lindoso
Journal:  Am J Trop Med Hyg       Date:  2015-10-19       Impact factor: 2.345

Review 5.  An update on pharmacotherapy for leishmaniasis.

Authors:  Shyam Sundar; Jaya Chakravarty
Journal:  Expert Opin Pharmacother       Date:  2014-10-25       Impact factor: 3.889

6.  Secondary Prophylaxis with Liposomal Amphotericin B in a Patient with Mucosal Leishmaniasis Undergoing Immunobiological Therapy for Active Ankylosing Spondylitis.

Authors:  Antonio Carlos Nicodemo; Heitor Franco de Andrade; Pablo Muñoz Torres; Valdir Sabbaga Amato
Journal:  Am J Trop Med Hyg       Date:  2019-08       Impact factor: 2.345

Review 7.  Liposomal drug delivery systems for the treatment of leishmaniasis.

Authors:  Felipe Francisco Tuon; Leticia Ramos Dantas; Regina Maia de Souza; Victoria Stadler Tasca Ribeiro; Valdir Sabbaga Amato
Journal:  Parasitol Res       Date:  2022-09-16       Impact factor: 2.383

8.  Reactivation of mucosal and cutaneous leishmaniasis in a renal transplanted patient.

Authors:  Felipe F Tuon; Giovana Marina Bombonatto; Eveline Roesler Battaglin; Marcus Henrique Sakumoto; Valdir Sabbaga Amato; Raphael Abegão de Camargo; Antônio Carlos Nicodemo
Journal:  Am J Trop Med Hyg       Date:  2014-04-14       Impact factor: 2.345

Review 9.  Liposomal amphotericin B as a treatment for human leishmaniasis.

Authors:  Manica Balasegaram; Koert Ritmeijer; Maria Angeles Lima; Sakib Burza; Gemma Ortiz Genovese; Barbara Milani; Sara Gaspani; Julien Potet; François Chappuis
Journal:  Expert Opin Emerg Drugs       Date:  2012-11-20       Impact factor: 4.191

10.  Mucosal leishmaniasis mimicking T-cell lymphoma in a patient receiving monoclonal antibody against TNFα.

Authors:  Antonio Carlos Nicodemo; Daniel Fernandes Duailibi; Diego Feriani; Maria Irma Seixas Duarte; Valdir Sabbaga Amato
Journal:  PLoS Negl Trop Dis       Date:  2017-09-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.